L3VLUP
ProSign in

TAK · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TAKJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TAK
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTAKJNJ
Q3 20204 holders, $423m30 holders, $26.2bn
Q4 20205 holders, $549m32 holders, $26.6bn
Q1 20214 holders, $699m31 holders, $25.3bn
Q2 20214 holders, $476m37 holders, $25.6bn
Q3 20214 holders, $410m40 holders, $24.1bn
Q4 20212 holders, $111m33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 20223 holders, $69m33 holders, $26.9bn
Q3 20223 holders, $68m36 holders, $25.4bn
Q4 20225 holders, $208m35 holders, $27.6bn
Q1 20235 holders, $349m42 holders, $24.5bn
Q2 20235 holders, $353m38 holders, $25.0bn
Q3 20234 holders, $311m37 holders, $18.9bn
Q4 20235 holders, $374m31 holders, $19.0bn
Q1 20243 holders, $228m32 holders, $19.7bn
Q2 20244 holders, $243m35 holders, $20.4bn
Q3 20243 holders, $236m28 holders, $22.3bn
Q4 20243 holders, $271m37 holders, $20.4bn
Q1 20253 holders, $256m32 holders, $20.5bn
Q2 20252 holders, $257m31 holders, $18.4bn
Q3 20252 holders, $253m32 holders, $23.7bn
Q4 20254 holders, $355m29 holders, $27.8bn
Q1 20263 holders, $467m34 holders, $35.6bn
Q2 20263 holders, $410m33 holders, $39.1bn
TAK

Takeda Pharmaceutical Co Ltd

Holders
4
Reported value
$243m
Buyers
3
Sellers
1

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TAK (0)

None.

Only JNJ (31)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →